Artelo Biosciences Reports Clinical Progress Across Three-Drug Pipeline in 2025
核心洞察
Artelo Biosciences (搜索) completed a successful Phase 1 study for ART26.12, demonstrating favorable safety profile and predictable pharmacokinetics for this novel FABP5 (搜索) inhibitor targeting pain management.
The company reported positive interim Phase 2 results for ART27.13 in cancer anorexia-cachexia syndrome (搜索), showing over 6% weight gain at the highest dose compared to 5% weight loss in placebo group.
ART12.11, a proprietary CBD-TMP cocrystal composition, received favorable UK MHRA regulatory guidance with plans to initiate first-in-human studies in the first half of 2027.
Artelo Biosciences (搜索), Inc. (Nasdaq: ARTL) reported significant clinical progress across its three-drug pipeline in 2025, marking what CEO Gregory D. Gorgas called "a pivotal year clinically" for the clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways.
ART26.12 Advances to Multiple Ascending Dose Study
The company successfully completed a first-in-human Phase 1 single ascending dose (SAD) study for ART26.12, its lead Fatty Acid Binding Protein 5 (FABP5 (搜索)) inhibitor. The study demonstrated a favorable safety profile with no serious adverse events, predictable linear pharmacokinetics, and dosing flexibility in both fed and fasted states. Based on these results, Artelo is preparing to open enrollment for the multiple ascending dose (MAD) study in the third quarter of 2026.
Preclinical efficacy data further strengthened ART26.12's profile, showing sustained analgesic effects without tolerance in an osteoarthritis (搜索) pain model, with efficacy comparable to naproxen and a potentially safer profile. The compound is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic, initially targeting chemotherapy-induced peripheral neuropathy (搜索) (CIPN).
Cancer Cachexia Treatment Shows Promise
ART27.13, a novel cannabinoid receptor agonist, demonstrated positive interim Phase 2 results in the Cancer Appetite Recovery Study (CAReS). The randomized, placebo-controlled trial showed improvements in body weight, lean body mass, and physical activity alongside a favorable side-effect profile in patients with cancer anorexia-cachexia syndrome (搜索).
The interim analysis revealed a mean weight gain of over 6% for participants receiving the highest dose of ART27.13, compared to a 5% weight loss in the placebo group. This finding is particularly significant as weight loss of more than 5% can predict poor outcomes for cancer patients and lower response to therapy. Currently, no FDA-approved treatment exists for cancer anorexia-cachexia syndrome (搜索).
Originally developed by AstraZeneca plc, ART27.13 selectively targets peripheral cannabinoid (CB1 (搜索) and CB2 (搜索)) receptors to avoid psychoactive side effects typically associated with cannabinoids. The compound is administered orally once daily with treatment goals to improve appetite, body weight, and activity levels while preserving muscle and elevating quality of life.
CBD Cocrystal Formulation Receives Regulatory Support
Artelo received favorable UK MHRA regulatory guidance supporting Phase 1 study plans for ART12.11, a proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (搜索) (TMP). Pending toxicology study results in 2026, the company plans to initiate human clinical studies with an oral solid dosage form during the first half of 2027.
Preclinical studies presented at the 35th Annual International Cannabinoid Research Society Symposium confirmed ART12.11's robust antidepressant-like activity in a stress-induced depression (搜索) model, with efficacy comparable to sertraline (Zoloft) and differentiated cognitive benefits not observed with leading SSRIs. The compound has exhibited better pharmacokinetics and improved efficacy compared to other forms of CBD in nonclinical studies.
Intellectual Property and Partnership Interest
The company strengthened its intellectual property position by receiving a Notice of Allowance from the European Patent Office covering the intended commercial formulation of ART27.13, extending patent protection through December 2041. This development, combined with clinical progress, has advanced partner interest in supporting the program's next stage of development.
Financial Performance
For fiscal year 2025, Artelo reported research and development expenses of $5.4 million, compared to $6.0 million in 2024. General and administrative expenses increased to $6.0 million from $4.1 million in the prior year. The company reported a net loss of $12.9 million, or $12.52 per basic and diluted common share, compared to a net loss of $9.8 million in 2024. Cash and investments totaled $0.6 million as of December 31, 2025.